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Clinical development of novel therapeutics begins with a coordinated sequence of early phase clinical trials. Such
early human studies confront a series of methodological and ethical challenges. In what follows, I propose a
theoretical framework for early human studies aimed at informing the negotiation of these challenges. At the
outset of clinical development, researchers confront a virtually undifferentiated landscape of uncertainty with
respect to three variables: outcomes, their probability of occurrence, and operation dimensions needed to
effectuate favorable outcomes. Early human trials transform this uncertain landscape into one where there are
grounds for belief about risk and benefit for various combined operation dimensions. To accomplish this, studies
set out with two aims. First, they identify a set of operation dimensions that, when combined as a package
(intervention ensemble), elicits a reasonable probability of a target outcome. Second, they define the boundaries of
dimension values within an intervention ensemble. This latter aim entails exposing at least some volunteers in early
studies to treatments that are inactive or excessive. I provide examples that illustrate the way early human studies
discover and delimit intervention ensembles, and close by offering some implications of this framework for ethics,
methodology, and efficiency in clinical development of new interventions.
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Introduction
Initial tests of new therapeutic strategies in human trials
are a key step in clinical translation. While widely
viewed as necessary for drug development, they fre-
quently draw debate about design, risk, and subject pro-
tection. Do phase 1 studies that enroll patients with
advanced disease ‘collude’ with unrealistic expectations
of desperate volunteers [1]? Should protocols enrolling
patients employ designs that maximize the chances for
patient benefit [2]? Should phase 1 studies be presented
to cancer patients as a treatment option [3]?
Addressing these questions and evaluating specific
protocols for ethical and scientific merit should start
with an accurate description of what early human stud-
ies (commonly glossed as phase 1 and 2 trials) are, and
what they set out to accomplish. In what follows, I buildCorrespondence: jonathan.kimmelman@mcgill.ca
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reproduction in any medium, provided the oron prior theoretical accounts of early human studies and
propose a framework for understanding their goals and
methods. The ethical planning and implementation of
early studies requires coordinating a series of investiga-
tions of an intervention with each other; the analysis
offered below aims to provide greater purchase on vari-
ous ethical, technical, and coordination problems
encountered in early human studies.Premises and terminology
Developing a theoretical framework of early human trials
requires clarifying terminology. In what follows, I use
‘early human trials’ to capture a large family of study
types, including what are variously called phase 0 trials,
pilot studies, translational trials, feasibility studies, phase
1 trials, dose-ranging trials, dose-finding trials, and many
kinds of phase 2 trials.
I distinguish ‘early human studies’ from ‘phase 1 trials’.
The latter is a regulatory term, rather than a methodo-
logical or scientific one. It has a strict definition directedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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human investigations that share similar overall objec-
tives, but are unregulated (e.g. initial tests of surgeries)
or that go under different labels.
Early studies involve a sequence of investigations ra-
ther than a single test. Multiple phase 1 trials, aimed at
answering different questions, often precede phase 2
trials, and new phase 1 trials are often conducted long
after a drug has completed phase 2 trials. For example,
the cancer drug erlotinib was first introduced into phase
1 trials before 2001 [5], yet since approval in 2004, phase
1 trials targeting new indications [6] or in combination
with other approved anti-cancer agents have been con-
ducted [7]. ‘First in human’ trials, the most stereotyped
category of phase 1 trials in the ethics literature, repre-
sent a minority of all early human trials.
Many early human trials are described as having ‘dose’
as the independent variable and ‘safety’ as the dependent
variable. However, early human trials manipulate vari-
ables other than dose, especially in the context of com-
plex interventions. And they observe other sorts of
dependent variables. For example, early studies collect
provisional indication of biological activity, often
through pharmacodynamic outcomes; investigators need
to know something about response in order to design
later trials.
In sum, early human trials involve a suite of investiga-
tions, all of which gather evidence about different
aspects of the intervention. I begin this analysis with the
uncontroversial ethical premise that a suite of early stud-
ies ought to minimize the number of subjects, and their
level of risk, for gathering adequate evidence to support
late-phase, confirmatory trials.
Early human trials and uncertainty
Early human trials are conducted at the point of highest
uncertainty in clinical development of an intervention.
As noted elsewhere, these uncertainties are different in
character from those encountered in late stages of inter-
vention development [8]. Uncertainties in late stages can
be articulated in terms of a defined set of variables,
discrete outcomes, and narrowly bounded estimates of
probabilities. For instance, investigators anticipate cer-
tain kinds of toxicities and clinical responses, and they
can assign probabilities for each. In early stages of inter-
vention development, investigators encounter uncer-
tainty. Decision science often calls the former kind of
uncertainty ‘risk’, and the second, ‘ignorance’. As Djulbe-
govic observes, uncertainties encountered in drug devel-
opment have a strict temporal relationship with each
other: ignorance about new drugs must be resolved be-
fore researchers can address more discrete questions of
risk. Research designs should be suited to the type ofuncertainty encountered by drug developers [8,9]. Ac-
cordingly, the goal of early human studies is to trans-
form ignorance in early stages of drug development into
risk by identifying conditions where there are reasonable
grounds for believing a drug has clinical utility [8]. The
goal of later phase trials is to reduce this risk by rigor-
ously confirming clinical utility using randomized trial
designs.
Early human studies confront three forms of ignor-
ance. The first is outcome uncertainty. When initiating
human studies, investigators often have little basis for
anticipating many toxicities. They may even have a foggy
view of what aspects of disease will respond. The second
uncertainty is probabilistic. In early human studies,
investigators are unable to assign reasonably bounded
probabilities for those outcomes that are anticipated.
The third uncertainty concerns intervention activities,
which I hereafter call operation dimensions. New drugs,
biologics, surgeries, et cetera only acquire therapeutic
activity by coordinating them with various other prac-
tices, knowledge, and materials (an ‘intervention ensem-
ble’). For example, at the point human investigations are
initiated, researchers do not yet know which dose of
drug to apply, or how frequently to apply the treatment.
Some dimensions, like dose, are known in advance to be
consequential even if their values are not known. Other
dimensions are only discovered in the course of human
studies. The discovery of unexpected cardiotoxicity in
early human studies, for example, can lead researchers
to discover concurrent cardiac monitoring as a necessary
operation dimension for safe and effective intervention.
The uncertainties confronted in initiating human stud-
ies are not boundless. Preclinical studies, prior clinical
evidence, and knowledge of biology often provide
grounds for believing that, say, picomolar quantities of
drug will not cause toxicity. Within these wide bounds,
however, investigators confront a virtually undifferenti-
ated landscape of uncertainty with respect to a dimen-
sion’s value given a target outcome. Thus, for example,
before early human investigations are conducted, investi-
gators have no solid grounds for believing that any one
dose will outperform another with respect to risk/bene-
fit. Early human investigations set out to transform this
landscape of uncertain outcomes, probabilities, dimen-
sions and values into one where there are grounds for
belief about the risk/benefit balance for an intervention
ensemble.
This transformation entails two complementary re-
search practices. First, investigators set out to identify a
set of operation dimensions (that is, the identity of the
dimensions and values) that, when combined as a pack-
age, elicits a reasonable probability of a target outcome,
such as disease response with acceptable toxicity or
serum levels of a drug with acceptable toxicity. For
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schedule, and the patient group in whom an anti-cancer
drug is likely to produce tumor shrinkage with accept-
able toxicity. This process of clarifying operation dimen-
sions within an intervention ensemble is necessary for
advancing a drug to later stages of clinical testing, be-
cause it would be costly and burdensome to use large
populations in late human trials to test intervention
ensembles that do not have a defined and favorable
probability of achieving a target outcome.
Second, investigators set out to define the boundaries
of dimension values in this intervention ensemble. That
is, early human investigations clarify dimension values
that demonstrably belong outside a space of combined
operation dimensions that produce an intended risk/
benefit. This latter process is just as crucial as the first:
it allows investigators to better plan subsequent trials,
and it resolves important questions for clinical practice.
This process of defining boundaries is ethically nettle-
some, because it necessarily entails exposing some
patients to ineffective and/or unsafe intervention
ensembles.
Consider a drug given to patients to prevent neuronal
injury following stroke. One key dimension for eliciting
clinical utility is timing of administration. If investigators
fail during clinical development to ever clarify the latest
time after stroke in which the drug provides neuropro-
tection, investigators risk either designing late phase
trials in which real treatment effects are diluted due to
implementation of a wide window of drug delivery, or
they risk designing needlessly rigid and expensive phase
2 studies that replicate precisely dimension values identi-
fied in phase 1. In any event, if the drug is shownFigure 1 How early trials proceed with respect to a single dimension. In
dose. (A) The investigators begin the study at a value that exceeds an ethical
knowledge gain will redeem burdens and risks of drug administration). (B) In
(which could be a pharmacokinetic variable, or a biological response of some
They continue escalating and eventually re-cross a target effect threshold (D)
effect threshold, but well before re-crossing the ethical threshold, they discon
elsewhere in the study, but enable warranted belief about the upper boundaeffective in late phase trials, failure to define boundaries
leaves physicians and healthcare systems uncertain about
how best to apply an intervention.
Early human studies do not resolve all uncertainties. They
do not define boundaries for every relevant dimension
value in an intervention ensemble. There can be practical
reasons why boundary values of certain dimensions are im-
portant to learn early in development. There can also be
practical reasons where knowing boundaries is less import-
ant or impossible to clarify. This might occur if a drug is
very safe and cheap, or if the fall-off of risk-benefit outside
the therapeutic window is believed to be so steep that deliv-
ery of drug outside the window to establish boundaries
would be unethical. Some boundaries are clarified only in
later stages of development, and the precise boundaries of
an intervention ensemble can be impossible to resolve in
early human studies, because the signal needed to resolve
some uncertainties can require large sample sizes. Early
studies often lack the statistical power to optimize dimen-
sion values inside the intervention ensemble. Instead, the
goal of early human studies is to find at least one interven-
tion ensemble that is a compelling candidate for confirm-
ation in late phase trials.
This account of early phase studies builds on various
themes in the methodological literature on phase 1
trials. Steven Piantadosi [10] and Benjamin Djulbegovic
[8], for example, describe translational trials and early
phase trials, respectively, as aimed at reducing uncer-
tainty. The former describes ‘translational trials’ as aimed
at information gain concerning drug properties, defined
formally in terms of entropy, rather than demonstration
of clinical promise: ‘Many clinical outcomes [in transla-
tional trials] are equally informative about the treatmentvestigtors do not yet know the value for a given dimension, such as
threshold (that is, value for which there is warranted belief that
vestigators escalate dimension values and cross a target effect threshold
sort). They have now defined the lower edges of dimension values. (C)
. When there are solid grounds for knowing they have crossed this target
tinue escalation. The burdens or risks in (D) are considerably higher than
ries of therapeutic dimension values.
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describes phase 1 and 2 trials in terms of helping to
shape uncertainty about a new drug.
Though various commentators [11] discuss the neces-
sity of identifying ‘optima’, ‘inflexion points’, or ‘bracket-
ing the anticipated optimal dose’ [10], boundary
identification across different dimensions, and assembly
of intervention ensembles, is not a major focus of prior
accounts of early human studies. The description offered
here, depicted graphically for a single dimension in
Figure 1, builds on prior accounts by drawing attention
to the problem of maximizing the efficiency with which
operation dimensions are identified, and boundaries
defined across a series of early human studies. Maximiz-
ing efficiency of intervention ensemble definition is de-
sirable because it minimizes the number of subjects
exposed to inactive or ineffective interventions in
drug development. For example, if early human trials
in stroke fail to define the appropriate time for deliv-
ery of a neuroprotective drug, many patients in later
human trials will likely be exposed to inactive appli-
cation of the drug. Maximizing is also critical for
minimizing expenditure of scarce resources, like equip-
ment or investigator expertise, during clinical translation.
Early human trials in practice: examples
Dose provides the clearest illustration of how early
human trials define dimension and their value boundar-
ies. Typically, a phase 1 trial begins by delivering drug at
the lowest plausible level where a biological effect, such
as a toxicity, might be observed. Studies administer es-
calating doses until toxicities are observed. Target modu-
lation or a surrogate of efficacy might be concurrently
monitored. Volunteers receiving insufficient or toxic
doses define the boundaries of the dose dimension for
further clinical testing. Nevertheless, dose is but one di-
mension that is explored through early human trials (see
Table 1 for examples).
Therapeutic co-interventions
Many drugs require co-interventions to unlock their
clinical utility. Early human trials provide an opportunity
to identify these co-interventions and their dimension
values.
Telaprevir was developed as an inhibitor of hepatitis C
virus replication. Initial phase 1 studies in patients with
chronic disease found that, when given at a dose of 750
mg, telaprivir reduced viral load. However, viral load
rapidly rebounded in most patients. A later small, single-
arm, early human trial tested telaprevir in combination
with two standard treatments for chronic hepatitis C:
pegylated interferon alpha 2a and ribavirin [12]. Patients
receiving interferon and ribavirin treatment showed a
sustained viral response after receiving telaprevir. Now,the question was how long to give each co-intervention,
and whether one could be dropped. Variations of the
combination therapy were tested in phase 2 studies.
These confirmed the utility of combining all three drugs.
The combination therapy later demonstrated efficacy in
phase 3 trials [13].
Populations
Often, anticancer drugs enter development without a
clear picture of which malignancies will respond. To dis-
cover the malignancy types to target in later trials and
the ones to exclude, early phase trials sometimes sample
patients with various malignancies.
Sometimes, however, early human trials are not exe-
cuted in a manner that establishes boundaries for a tar-
get population. Consider the case of cetuximab, a
monoclonal antibody that binds to and inactivates the
epidermal growth factor receptor (EGFR) [14]. Molecu-
lar knowledge led investigators to pursue all prelicensure
trials in colorectal cancer patients with EGFR-expressing
tumors. The agent received regulatory licensure in 2004.
Retrospective analysis of phase 2 results, however, did
not show consistent relationships between EGFR expres-
sion and clinical activity. Some medical centers thus
began offering cetuximab off-label to colorectal cancer
patients with non EGFR-expressing tumors. Retrospect-
ive review of patient outcomes confirmed that, contrary
to the FDA label, cetuximab response bore no relation-
ship with EGFR expression [15]. In this episode, there
were theoretical reasons to limit trials to patients expres-
sing EGFR. However, by not testing this theory in preli-
censure trials, drug developers missed opportunities to
define boundaries of the target population. Though
cetuximab was licensed successfully, this failure to define
boundaries exacted inefficiencies for healthcare systems
and practitioners, who confronted uncertainties sur-
rounding the right patient population for this very ex-
pensive but potentially life-saving drug.
Delivery
Treatments often raise questions about how best to de-
liver an intervention. Throughout the 1990s, several
teams claimed to have stabilized Parkinson’s disease by
striatal implantation of fetal tissues. The first two rando-
mized, sham controlled trials of the approach, however,
failed to demonstrate statistical significance on the pri-
mary endpoint. They also uncovered previously
unrecognized graft-induced dyskinesias [16]. A decade
later, investigators are proposing to reinitiate transplant
trials [17].
Among the many outstanding dimensions of the strat-
egy is delivery. Unsuccessful randomized studies
implanted cells in the striatum. However, some early
studies support the targeting of structures adjacent to
Table 1 Common dimensions in intervention ensembles
Examples Cetuximab Belimumab Gene transfer for AID-
SCID
Treatment dimension
Dose mg/kg; cells; vector
particles. . .
250 mg/m2 10 mg/kg ≥8 × 10^6 cells




3× @ 2-wk intervals; 4-wk
intervals after
Administration/target Infusion; oral; intratumoral. . . Intravenous infusion Intravenous infusion Intravenous infusion
Co-intervention Radiotherapy;
immunosuppresion. . .
Standard of care Non-myeloablative
conditioning






Timing delivery Symptom onset; 12 h after
event. . .
After irinotecan or oxaliplatin
failure
3 weeks after stopping
PEG-ADA
Population dimensions
Diagnostic criteria Marker positivity; diagnostic
score. . .
KRAS mutation in codon 12
or 13
α-nuclear Ab titer≥ 1:80 and/or α-
dsDNA
Contraindications Concurrent infection;
clothing disorder. . .
Prior anaphylaxis to belimumab Neutralizing Abs to vector
(AAV8)
Indications Disease; injury; at-risk
population. . .
Metastatic colorectal cancer Active systemic lupus
erythematosus (SLE)
ADA-SCID
Age Adults Non-geriatric adults Children
Outcome dimensions
Endpoint Change on scale; time to
event. . .
Survival SLE responder index Immune system
reconstitution
Duration Short term; ‘long term’
remission. . .
1 year Permanent
Kimmelman Trials 2012, 13:173 Page 5 of 8
http://www.trialsjournal.com/content/13/1/173the striatum. Another unresolved issue is whether the
entire striatum should be targeted, or merely structures
within the striatum. Still another outstanding uncer-
tainty concerns the type of cannula used to deliver cells:
too large a diameter damages the site of delivery, which
leads to death of transplanted cells; too small a cannula
necessitates single-cell suspensions of fetal tissue, which
can also lead to cell death [18]. Given the high level of
neurosurgical risk and the scarcity of fetal tissues, an
important task for early human studies will be to clarify
the gross advantages for using particular techniques of
delivery. This uncertainty might be resolved within a sin-
gle protocol, or by running several parallel studies using
different techniques [17]. Of course, coordinated studies
or single studies aimed at resolving values for multiple
dimensions entail non-trivial costs in terms of logistics
and statistical efficiency.
Endpoints
Early human trials also clarify the kinds of endpoints
sought in later trials. Belimumab is the first drug ever
approved specifically for the treatment of systemic lupus
erythematosus. The first phase 2 trial of belimumab
failed to meet the co-primary endpoints of disease activ-
ity at 24 weeks and time to first flare during the 52
weeks. However, re-analysis of trial data indicated that asubset of patients, those with B-cell dysfunction, had
indeed improved using a different measure of lupus re-
sponse, the SRI. Human Genome Sciences then designed
two phase 3 studies enrolling only patients with B-cell
dysfunction, and using SRI as the primary endpoint.
Both studies met their primary endpoints, leading to
FDA approval [19].
Many newer, targeted, cancer drugs work by inhibiting
tumor growth [20]. Standard criteria for measuring anti-
cancer activity, like RECIST, can fail to detect otherwise
potent activity. There is no reason why phase 1 trials in
cancer or other disease areas cannot be used to explore
a series of different endpoints so that the most appropri-
ate ones are selected for primary endpoints in phase 2
trials [21]. Pharmacokinetic and pharmacodynamic end-
points can also provide crucial inputs for selecting
values on dimensions like dose, schedule, or delivery.
Discussion
To examine how this framework might assist decision-
makers with negotiating ethical and methodological
problems in testing new interventions, consider three
challenges: ethical justification of risk, subject selection,
and study design.
Some commentators contend that risks in phase 1
trials can be justified by therapeutic value. This carries
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be presented to volunteers during informed consent as
therapeutic opportunities. The analysis provided above
reinforces criticisms of this position. As noted above, a
key aim of early phase studies is establishing boundaries
on values of each dimension. Occasionally, there can
very compelling and reliable grounds for knowing these
boundaries a priori. More typically this is not the case,
and the task of boundary definition imposes a require-
ment that some patients receive inactive and/or harmful
intervention ensembles. During the course of drug de-
velopment, some studies should expose patients to in-
active or excessive doses, and some patient classes
should be uncovered as ineligible for future investiga-
tions of the intervention ensemble. Though investigators
should not know in advance which patients will receive
harmful intervention ensembles, they should expect that
if a study has been properly implemented, at least some
patients will be exposed. As argued elsewhere, [22] be-
cause the principle of justice dictates that harm to one
patient cannot be ‘purchased’ with benefit received by
another, risk in early human studies cannot be justified
by appeal to therapeutic benefit. This view is captured
by John O’Quigley’s observation that ‘in the areas of
phase 2, 3 and 4 studies, the scientific approach guiding
the statistician. . . and guiding the clinician are in. . . har-
mony. This is not so. . . for phase 1 dose-finding studies’
[11]. I would suggest this argument also holds for phase
2 studies that are still searching for dimension values, as
when studies randomize patients to two different doses.
A second ethical and design problem in early human
trials is subject selection. Geron’s phase 1 trial testing
GRNOPC1, an embryo-derived treatment candidate for
spinal cord injury, was controversial. Some criticized
Geron for enrolling patients with recent injury, since a
small probability of modest spontaneous recoveries
might be abrogated by side effects of cell delivery [23].
Others countered that the subject selection was sensible,
since patients with recent injury were more likely to
benefit [24]. The analysis provided above can help ad-
dress this dispute. At the point of trial initiation, Geron
investigators confronted numerous second order uncer-
tainties: how should cells be delivered? Can transient im-
munosuppression prevent rejection of delivered cells?
What dose of cells can be delivered safely? Can cells
stimulate recovery? The key question for trialists was
how such uncertainties could be resolved with the low-
est risk and smallest number of patients exposed to
identify an intervention ensemble that could be
advanced to randomized trials. If key uncertainties like
safety, delivery, and immunosuppression could be rea-
sonably resolved in patients at lower risk, Geron might
have minimized risk and burden by initiating their study
first in a cohort of patients with prolonged injury. Withthese dimensions mapped they might then have moved
to patients with more recent injury to explore dimen-
sions that require an efficacy signal.
A third common challenge arises in studies involving
high-risk interventions. Trials testing biologics for treat-
ing brain disorders are one example briefly visited in the
previous section. In contrast to dose escalation trials,
these studies typically explore very few intervention
ensembles. This parsimonious approach to exploring di-
mension variables may actually lead to early study ineffi-
ciencies. For instance, in a Parkinson’s disease gene
transfer candidate phase 1 trial, investigators varied one
dimension value, dose, and only by a single increment
[25]. The subsequent randomized trial failed to meet its
primary endpoint, though it trended positively and met
secondary endpoints [25]. Should the study count as a
negative one, and the candidate be redesigned, or does
the hint of signal support new trials? The authors of the
report suggested the phase 2 study might have failed to
implement the intervention in the optimal way: the 12-
month follow-up period for their primary endpoint may
have provided insufficient time for disease response to
emerge. They further speculated that delivery to an add-
itional brain target, the substantia nigra, might have
improved response. Clearly, then, the boundaries on the
values for two dimensions (earliest detection of efficacy
and delivery target) remain unanchored. A larger, more
systematic exploration of these dimensions in a phase 1
trial might have provided a better basis for identifying
an intervention ensemble that produced efficacy signal
in phase 2, hence ultimately sparing more patients of the
burdens of an ineffective intervention ensemble.
I close by discussing a few further implications, and
limitations of the framework offered above. Early studies
should consider ways to maximize the efficiency of ex-
ploring dimensions within a broader program of re-
search. Successful translational research programs will
eventually discover necessary operation dimensions, but
they may require more patients than necessary if this
discovery process is spread out over numerous trials that
are not well coordinated with each other. One option is
to consider designing phase 1 studies that systematically
explore a larger number of dimensions. Another option
is to design studies that explore a diverse space of com-
bined dimensions. For example, Piantadosi describes
two-drug combination dose-finding trials that map a
hypothetical ‘response surface’ by administering factor-
ials of two drugs at several doses. This approach, if adap-
tively applied, can have advantages in terms identifying
optimal combination doses with maximum efficiency
[10]. Such designs might be extended for other dimen-
sions within an intervention ensemble; I leave to others
how such multifactorial experiments might be designed
and reconciled with statistical efficiency.
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dictions. First, late human trials that apply intervention
dimension values that reside beyond the boundaries of
previously validated intervention ensembles are more
likely to fail translation than trials that employ interven-
tions within boundaries. This may seem trivial. However,
it is an open question how frequently later trials use
intervention ensembles where there is evidence to sug-
gest they reside beyond the boundaries of a promising
intervention ensemble. Second, completion of transla-
tion trajectories is likely to be more efficient where they
begin by carefully mapping dimensional boundaries. All
else being equal, trajectories that have not mapped
boundaries early on should require more phase 3 trials
to produce demonstrable evidence of therapeutic value.
Third, healthcare systems are likely to encounter greater
inefficiency in applying interventions where dimensional
boundaries have not been well defined in early human
studies as compared with interventions where they have
been well defined. These inefficiencies would be
reflected in relabeling of drugs, or widespread applica-
tions of an intervention that are off label and not well
supported by clinical evidence. With some additional
work, each of these predictions can be formulated as a
testable hypothesis.
An important limitation of the above framework is its
ideality. Drug development is constrained by many non-
epistemic variables, including financial and recruitment
difficulties. The framework offered here provides little
guidance about how evidentiary aims ought to be pur-
sued within the practical constraints of drug develop-
ment. If a biotechnology company can only budget for a
single phase 1 trial, perhaps it makes ethical sense to
‘bet the house’ on one or two intervention ensembles ra-
ther than systematically explore others. I leave for a later
analysis how this framework is reconciled with these ser-
ious practical challenges. A second limitation is that
boundaries are often resolved at later stages of drug de-
velopment, as when biomarkers of response are identi-
fied in large populations. Therefore, the framework
provided above is, to a lesser degree, also applicable in
later stages of drug testing.
And there are unsettling implications as well. This
framework undermines the position, frequently mooted
in the trial ethics literature, that early human trials pur-
sued in desperately ill volunteers can be viewed as thera-
peutic endeavors. However, burdens entailed in some
early human trials are substantial. For instance, the
probability of drug-related death in cancer phase 1 trials
is 0.5% [26], and almost the same for fatal cerebral
hemorrhage in Parkinson’s cell transplantation studies
[27]. If one accepts the views that: (a) advancing drug
translation with reasonable efficiency is simply impos-
sible without designing trials that define boundaries, and(b) therapeutic translation should be prosecuted with
reasonable efficiency, then the framework suggests that
parties to drug translation must come to terms with the
position that studies that expose patients to nonthera-
peutic research procedures that carry substantial risk of
death can, at least in special circumstances, be ethical.
These concerns and limitations aside, this analysis
extends our understanding about the aims and architec-
ture of early human trials within the context of a
broader program of research. A clear description of the
framework supporting early trials is critical for meaning-
ful progress in resolving persistent ethical and methodo-
logical debates surrounding such studies.
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